Kairos Pharma, Ltd.
KAPA
$0.9074
-$0.077-7.82%
AMEX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 45.28% | -9.66% | 1.67% | 719.70% | 104.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.45% | 4.72% | 127.78% | 505.00% | 131.45% |
| Operating Income | -33.45% | -4.72% | -127.78% | -505.00% | -131.45% |
| Income Before Tax | -235.58% | -7.20% | -121.23% | -470.41% | -33.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -235.58% | -7.20% | -121.23% | -470.41% | -33.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -235.58% | -7.20% | -121.23% | -470.41% | -33.33% |
| EBIT | -33.45% | -4.72% | -127.78% | -505.00% | -131.45% |
| EBITDA | -38.87% | -5.81% | -187.21% | -649.29% | -194.05% |
| EPS Basic | -217.88% | -5.26% | -117.02% | -458.95% | -32.46% |
| Normalized Basic EPS | -217.46% | -4.90% | -117.05% | -457.98% | -32.17% |
| EPS Diluted | -217.88% | -5.26% | -117.02% | -458.95% | -32.46% |
| Normalized Diluted EPS | -217.46% | -4.90% | -117.05% | -457.98% | -32.17% |
| Average Basic Shares Outstanding | 5.57% | 2.21% | 2.21% | 1.85% | 0.81% |
| Average Diluted Shares Outstanding | 5.57% | 2.21% | 2.21% | 1.85% | 0.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |